The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line treatment paradigms with strong growth driven by CAR-T and bispecific antibodies. Leading contenders advancing ...

Elranatamab monotherapy achieved a statistically significant improvement in progression free survival vs daratumumab/pomalidomide/dexamethasone in patients with R/R ...

The types of active multiple myeloma are categorized by the overproduced immunoglobulin, with IgG being the most common and IgE the rarest and most aggressive. Smoldering multiple myeloma is a ...

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more ...

There is a huge unmet medical need in the treatment of multiple sclerosis (MS), with many neurologists believing that without effective therapies, most patients will never be able to come off disease ...

Multiple myeloma is a cancer of the blood that affects plasma cells, and its progression is determined using the Durie-Salmon Staging System or the Revised International Staging System (RISS). The ...